Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Japanese ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

(Reuters) - Business leaders in Davos joined calls by U.S. President Donald Trump for the European Union to speed up efforts ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

CAG reported handling a total of 1.99 million tonnes of airfreight in 2024, up 14.6 per cent from 2023. Read more at straitstimes.com.

(Legal Fee Tracker is a weekly feature focused on attorney compensation. Please send tips or suggestions to ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.